Treatment of Sezary syndrome.
D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003873:Dermatitis, Exfoliative / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D007645:Keratoderma, Palmoplantar / Q000188:drug therapy* / Q000532:radiotherapy; D008206:Lymphatic Diseases / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008223:Lymphoma / Q000532:radiotherapy; D008558:Melphalan / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011537:Pruritus / Q000188:drug therapy; D012075:Remission, Spontaneous; D013577:Syndrome; D013997:Time Factors; D014265:Triethylenemelamine / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use
D009588:Nitrogen Mustard Compounds; D002699:Chlorambucil; D014747:Vinblastine; D003520:Cyclophosphamide; D014265:Triethylenemelamine; D008558:Melphalan; D011241:Prednisone; D008727:Methotrexate